Patrick Amstutz, Molecular Partners CEO
Another one bites the dust: Novartis, Molecular Partners and their antiviral get the boot from NIH Covid study
Molecular Partners CEO Patrick Amstutz knew going into the NIH’s ACTIV-3 study that the bar for ensovibep was “very high.” A slew of Covid-19 antibodies …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
